Cerevance announced that it will present two poster studies featuring its investigational therapy Solengepras (also known as CVN-424) at the 2025 Parkinson Study Group (PSG) Annual Meeting, scheduled December 4-6 in San Diego.
The first poster will cover results from a Phase 2 adjunctive study, titled “Characteristics of OFF Time Improvement in a Phase 2 Study for Parkinson’s Disease with Solengepras”, focusing on reductions in OFF time—a key unmet need in Parkinson’s therapy. The second poster is titled “Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Early Parkinson’s Disease”, and reflects data from the Phase 2 ASCEND trial exploring solengepras as monotherapy in early-stage Parkinson’s disease.
Solengepras is designed as a once-daily, oral, non-dopaminergic treatment targeting the GPR6 receptor. Unlike traditional dopamine-pathway interventions, Cerevance says the drug aims to modulate the brain’s indirect pathway, potentially improving both motor and non-motor symptoms while reducing risks such as dyskinesias and motor fluctuations. The upcoming presentations come ahead of the Phase 3 ARISE trial of solengepras as an adjunctive therapy to levodopa, for which topline results are expected in the first half of 2026.
While the data to be shown are preliminary and patients remain in active trials, the disclosure marks a key visibility event for Cerevance’s Parkinson’s programme and may set the stage for regulatory and commercial discussions later in the development cycle.
